LISI : 2011 Annual results

Press release
Belfort, February 16, 2012

LISI REPORTS SIGNIFICANT IMPROVEMENT IN RESULTS FOR 2011

Sales revenue increase 19.1% to €925 M
Strong organic growth: +13.8%
Dynamic performance from the Aerospace Division in Europe
Solid results for the Automotive Division
Return to profitability confirmed
EBIT: €76.6 M (+ 54.9 %)
Further improvement in operating margin: 8.3% (+1.9 points)
Financial structure still very solid after acquisitions in 2010 and 2011
Positive free cash flow: €6.4 M, after a 28% increase in capital expenditures
Rise in average ROCE: 13.3 % (+3.3 points before corporate tax) Further increase in the dividend: up 24% to €1.30 per share Good general outlook, supported by numerous projects
Belfort, February 16, 2012 - LISI's Board of Directors, chaired by Chairman Gilles Kohler, reviewed the final accounts for the financial year ending December 31, 2011. They will be submitted for approval at the General Meeting on April 26, 2012.

12 months ending December 31, 2011 2010 Change

Key elements of the income statement
Sales revenue €M 925.1 776.7 + 19.1% EBITDA €M 122.1 95.7 + 27.6% EBITDA margin % 13.2 12.3 + 0.9 pts EBIT €M 76.6 49.5 + 54.9% Current operating margin % 8.3 6.4 + 1.9 pts Earnings attributable to holders of company equity €M 58.2 32.9 + 76.8% Net earnings per share € 5.61 3.19 + 75.9%
Key elements of the cash flow statements
Operating cash flow €M 95.3 79.5 + 19.9% Net CAPEX €M - 64.9 - 50.6 + 28.2 % Free cash flow (FCF) €M 6.4 54.8 - 88.3%
Key elements of the financial structure
Net debt €M 102.6 17.5 n.a.
Ratio of net debt to equity 18.9% 3.6% + 15.3 pts
Sales revenue increase 19.1% to €925 M
The significant increase in the LISI group's sales in 2011 can be explained as follows:
- the dynamism of the Aerospace Division in Europe and the acquisition of the Creuzet group, consisting of Creuzet Aéronautique and Indraero Siren, which generated €58.9 M, from which LISI AEROSPACE benefited (€407.6 M, +44.7%),
- the solid performance of the Automotive Division (€446.3 M, being + 11.2%),

1

- the contribution of LISI MEDICAL (€74.0 M) particularly due to its "Orthopaedics" branch, which more than compensated up for the disposal of LISI COSMETICS, which was sold in April 2011 (2010 sales: €52.8 M).
At constant scope and exchange rates, organic growth was 13.8%, compared to 3.5% in 2010. It gradually slowed down during the year, before being boosted by external growth with the integration of the Creuzet group; this acquisition alone accounted for approximately 12% of instantaneous growth in the second half of the year.

	LISI Consolidated	Of which LISI AEROSPACE	Of which LISI AUTOMOTIVE	Of which LISI MEDICAL
Q1	+23.7%	+16.3%	+28.4%	+297.0%
Q2	+11.5%	+16.7%	+10.2%	+246.4%
Q3	+25.4%	+69.9%	+9.1%	+51.3%
Q4	+16.8%	+77.5%	-1.4%	-22.7%
2011	+19.1%	+44.7%	+11.2%	+73.3%

The Group continued its policy of strengthening and building its positions in its strategic markets initiated in 2010 with a fundamental redefinition of its scope of activity and an ambitious capital expenditure program. It thus renewed more than a quarter of its portfolio of activities in 15 months.
The Group's activities are now more evenly balanced: LISI AEROSPACE accounts for 44% of consolidated sales, LISI AUTOMOTIVE for 48% and LISI MEDICAL for 8%.
Return to profitability confirmed
LISI AEROSPACE Fasteners was the main contributor to the improvement in the results, after a substantial decline in 2010, along with LISI MEDICAL, to a lesser extent. LISI AUTOMOTIVE reported a slight downturn despite an increase in activity (up €45 M). All of the management indicators have therefore improved, despite the disposal of LISI COSMETICS.
EBITDA reached €122.1 M, corresponding to 13.2% of sales and an increase of 27.6%. The improvement in the EBIT is particularly marked with €76.6 M (up 54.9%), due to reversals of provisions (+ €2.3 M in
2011 against - €0.4 M in 2010), despite the increase in depreciation (€47.7 M against €45.8 M in 2010). Strengthened by LISI AEROSPACE's significant contribution compared to the low point of 2010, the operating margin rose by 1.9 points in comparison to 2010.
The non-recurring costs in 2011 mainly consist of the capital gain from the disposal of LISI COSMETICS of
+ €9.8 M, and a provision associated with the possible disposal of assets in Germany of - €1.6 M. Financial expenses rose to - €1.9 M due to additional debt associated with the acquisition of the Creuzet group (Net debt of €102.6 M, resulting in interest costs of €4.2 M) and exchange gains on working capital (€1.5 M). Tax costs rose sharply, as a result, among other things, of an increase in corporate tax in France representing €1.6 M, and CVAE (tax on companies' added value)1 of - €4.7 M (- €3.4 M in 2010). The average apparent rate was 27.8% compared to 30.9% in 2010. Consequently, net earnings reached the historically high level of €58.2 M compared to €32.9 M in 2010, corresponding to an increase of 76.8%.

1 French business tax on added value

2

Net earnings per share in 2011 were €5.61 (€3.19 in 2010 and €0.92 in 2009); excluding non-recurring items associated with the disposal of LISI COSMETICS, earnings would be €4.66.
After returning to dividend growth in 2010, the Group will propose for approval at the shareholders' General Meeting to set the dividend at €xx per share for the financial year of 2011, corresponding to an increase of xx% compared to last year.
Financial structure still very solid after acquisitions in 2010 and 2011
2011 marked the completion of another stage in the ambitious industrial equipment and structural investment program launched in 2010 throughout the divisions: a total of €64.9 M was paid out. This was mainly dedicated to improving production and logistics facilities, to productivity and to new products in all divisions.
Up by nearly 20% to €95.3 M, operating cash flow was slightly above 10% of sales (10.3%). The Group has not only been able to finance its capital expenditures program, but also the increase in working capital requirements of €24.0 M (against a decrease in 2010 of €25.9 M). The WCR was €243 M on December 31,
2011, or 25% of sales, compared to €173 M in 2010 (21% of sales). Measures taken in relation to organization and productivity, and the implementation of improved logistics were not enough to compensate for the impact of very strong growth in the Aerospace Division and the sudden slowdown of activity at LISI AUTOMOTIVE at the end of the year.
After taking all of these elements into account, the Free Cash Flow remained positive, rising to €6.4 M (+
€54.8 M in 2010).
The acquisition of the Creuzet group, for a net amount of €68.1 M, was financed by the proceeds of the disposal of LISI COSMETICS and €75 M using the medium term credit lines available to LISI.
At €102.6 M, net debt remains below 20% of equity capital (18.9%). This represents 0.84 of the EBITDA, substantially below the prudential ratios required by the banks. Furthermore, available cash flow has virtually remained stable, at €68 M on December 31, 2011, compared to €73 M on December 31, 2010.
The capital employed increased from €561 M to €707 M, taking into account the consolidation excess allocated to acquisitions. The return on capital employed before tax improved to 13.3% compared to 10% in 2010.
LISI AEROSPACE
• Performance has reflected the correct anticipation, in 2010, of a return to growth
• The significant impact of the Creuzet group on sales (+ €59 M), growth focused on Europe, contribution from the United States again marginal
• Very favorable impact of the new A350 products and "fastracks" on European activity and on the operating margin
2011 2010 Change
Sales revenue (in €M) 407.6 281.6 +26.7%
At constant scope and exchange rates
Current operating margin 12.2% 6.8% + 5.4 pts Free cash flow (€M) 22.7 16.5 + 6.1 M€ As a % of sales revenue 5.6% 5.9% n.a

3

LISI AUTOMOTIVE
New market shares captured
Results under pressure:

o impact of the sudden slowdown in orders in December, due to the lack of time to adjust

o increased use of subcontractors

Recovery of sites that are still under-performing in progress
2011 2010 Change
Sales revenue (in €M) 446.3 401.3 +8.1%
At constant scope and exchange rates
Current operating margin 5.3% 6.2% - 1.0 pts Free cash flow (€M) - 11.5 27.3 - 38.8 M€ As a % of sales revenue n.a 6.8% n.a
LISI MEDICAL
First contribution of LISI MEDICAL as a separate division
Impact of the end of the building of inventory on the activity
Satisfactory contributions from LISI MEDICAL Orthopaedics and Jeropa (United States)
2011 2010 Change
Sales revenue (in €M) 74.0 42.7 -16.8%

At constant scope and exchange rates

Current operating margin 7.4% 5.0% 2.4 pts
Free cash flow (€M) 4.1 - 5.0 + 9.1 M€

As a % of sales revenue 5.5% n.a n.a

Outlook: acceleration in the Aerospace Division, progress in the Automotive and Medical

Divisions
After a crisis year in 2010 for the Aerospace Division, and the outstanding recovery of the Automotive Division, performances in 2011 have fully validated the Group's ambitious growth policy in terms of capital expenditure, innovation and gaining market share.
These performances were achieved in a mixed economic environment: it has been very positive for the aerospace market, which has fully recovered in Europe, but a little uncertain for the medical and automotive markets. While remaining solid, the latter has slowed down in a volatile context, with too much activity at the beginning of the financial year, followed by a sudden contraction towards the end of the year. Despite objectives generally being reached, the consolidated operating margin is still not at the normative level that the Group considers to be 10%.
The LISI Group has thus completed another step towards its objective of a two-figure consolidated operating margin, while at the same time maintaining a substantially positive Free Cash Flow.

4

All of the divisions will be called upon to contribute:
• The Aerospace Division has the potential for significant growth, mainly in the United States. The requirements of the large 2012 - 2022 contract obtained from BOEING, the start of the B787 and an increase in production rates should result in a larger contribution from the American platform. The Creuzet group's contribution over the next twelve months should also be significant, given that Indraero Siren should improve its performance.
• Several problems related to the Automotive Division's activity should be eliminated, notably in Germany, and it should benefit from investments and organizational initiatives undertaken in 2011. The potential for the operating margin to recover remains intact, so long as the volatility of demand from LISI AUTOMOTIVE's large customers does not disrupt the complex production line.
• The performances of the Medical Division's two "Fasteners" sites (in Lyon and Escondido in the United States) should see a significant improvement compared to 2011, while the "Orthopaedics" plant (in Caen) should develop a substantial volume of new products. 2012 will therefore be a key year in the consolidation of the LISI MEDICAL division.
The Group has covered all of its financial repayments for 2012 and 2013 with cash, overdraft facilities or medium term credit lines.
Supported by its experience and financial solidity, the LISI Group is pursuing its policy of targeted, profitable growth. Management and investment initiatives, aimed at completing numerous projects currently in progress and strengthening the Group's industrial excellence will be maintained.
The Group feels that the current outlook is generally positive and does not see any downturns in its markets; as a result, the Group should achieve, for the first time in its history, sales in excess of €1 billion in 2012.

Contact

Emmanuel Viellard
Telephone: [phone]
Email: [e-mail]
Website: www.lisi-group.com

The next announcements will appear after close of trading on Euronext Paris

Q1 2012 financial information: April 26, 2012

General Meeting of Shareholders: April 26, 2012

H1 2012 results: July 26, 2012

Q3 2012 Financial Information: October 24, 2012

LISI shares are listed on the Eurolist compartment B market and are part of the CAC MID 100 - Next 150 index under the ISIN code: FR 0000050353. LISI is a worldwide leading manufacturer of fasteners and assembly components for the Aerospace, Automotive, and medical implants industries. LISI MEDICAL specializes in the subcontracting of implants for groups developing medical solutions.

Reuters:GFII.PA Bloomberg:FII FP

5

LISI Group consolidated income statement

(In €'000) Notes 31/12/2011 31/12/2010

Pre-tax sales 925 095 776 689

Changes in stock, finished products and production in progress 25 668 3 699

Total production 950 763 780 388

Other revenues * 14 457 15 395

Total operating revenues 965 221 795 783

Consumption (275 698) (214 169) Other purchases and external charges (187 797) (160 810)

Value added 501 726 420 803

Taxes and duties ** (7 687) (6 459) Personnel expenses (including temporary employees) (371 952) (318 679)

EBITDA 122 087 95 665

Depreciation (47 718) (45 798) Net provisions 2 274 (399)

EBIT 76 643 49 467

Non-recurring operating expenses (2 931) (1 600) Non-recurring operating revenues 10 645 526

Operating profit 84 356 48 393

Financing expenses and revenue on cash (4 401) (2 517)

Revenue on cash 658 430

Financing expenses (5 059) (2 947)

Other interest revenue and expenses 1 588 1 592

Other financial items 9 942 13 135

Other interest expenses (8 354) (11 543) Taxes (of which CVAE (Tax on Companies' Added Value)** (24 270) (14 704) Profit (loss) from assets held for sale 805

Profit (loss) for the period 58 078 32 764

attributable as company shareholders' equity 58 225 32 924

Interest not granting control over the company (147) (161)

Earnings per share (in €) 5,61 3,19

Diluted earnings per share (in €) 5,61 3,19

(In €'000) 31/12/2011 31/12/2010

Profit (loss) for the period 58 078 32 764

Other elements of overall earnings

Exchange rate spreads resulting from foreign business 4 008 12 324

Tax charge on other portions of global income - -

Other portions of global earnings, after taxes 4 008 12 324

Total overall income for the period 62 086 45 088

attributable as company shareholders' equity 62 275 45 194

Interest not granting control over the company (189) (106)

LISI Group consolidated balance sheet

ASSETS

(In €'000) Notes 31/12/2011 31/12/2010

LONG-TERM ASSETS

Goodwill 182 611 152 287

Other intangible assets 15 382 17 054

Tangible assets 326 872 278 815

Long-term financial assets 5 642 5 394

Deferred tax assets 23 596 16 146

Other long-term financial assets 24 63

Total long-term assets 554 127 469 759

SHORT-TERM ASSETS

Inventories 238 879 177 096

Taxes - Claim on the state 915 1 198

Trade and other receivables 158 847 126 721

Other short-term financial assets 51 883 58 619

Cash and cash equivalents 45 675 22 261

Total short-term assets 496 199 385 896 TOTAL ASSETS 1 050 326 855 654 TOTAL EQUITY AND LIABILITIES

(In €'000) Notes 31/12/2011 31/12/2010

SHAREHOLDERS' EQUITY

Capital stock 21 573 21 573

Additional paid-in capital 70 803 70 803

Treasury shares (15 461) (15 028) Consolidated reserves 401 231 379 651

Conversion reserves 1 658 (2 392) Other income and expenses recorded directly as shareholders' equity 3 025 1 933

Profit (loss) for the period 58 225 32 924

Total shareholders' equity - Group's share 541 053 489 463

Minority interests 1 458 858

Total shareholders' equity 542 511 490 320

LONG-TERM LIABILITIES

Long-term provisions 48 177 39 023

Long-term borrowings 136 408 72 647

Other long-term liabilities 5 725 5 830

Deferred tax liabilities 38 387 34 859

Total long-term liabilities 228 697 152 359

SHORT-TERM LIABILITIES

Short-term provisions 14 737 15 232

Short-term borrowings* 63 788 25 709

Trade and other accounts payable 194 711 162 440

Taxes due 5 882 9 594

Total short-term liabilities 279 117 212 975 TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 1 050 325 855 654

* of which banking facilities 29 565 7 923

LISI Group consolidated cash flow table

(In €'000 31/12/2011 31/12/2010

Operating activities

Net earnings 58 078 32 764

Elimination of net charges not affecting cash flows:

- Depreciation and non-recurrent financial provisions 47 665 43 823

- Changes in deferred taxes (241) (694)

- Income on disposals, provisions for liabilities and others (8 700) 5 249

Gross cash flow margin 96 801 81 142

Net changes in provisions provided by or used for current operations (1 503) (1 669)

Operating cash flow 95 299 79 474

Income tax expense (revenue) 24 511 15 279

Elimination of net borrowing costs 4 009 2 525

Effect of changes in inventory on cash (33 562) (9 870) Effect of changes in accounts receivable and accounts payable 13 203 23 954

Net cash provided by or used for operations before tax 103 459 111 367

Taxes paid (28 138) (3 453)

Cash provided by or used for operations (A) 75 321 107 914

Investment activities

Acquisition of consolidated companies (100 001) (42 026)

Cash acquired 5 569 1 502

Acquisition of tangible and intangible assets (65 182) (51 974)

Acquisition of financial assets (0)

Change in granted loans and advances (150) 476

Investment subsidies received

Dividends received 2

Total cash used for investment activities (159 765) (92 016)

Disposed cash (6 476)

Disposal of consolidated companies 31 920

Transfer of tangible and intangible assets 277 1 359

Disposal of financial assets 22 5

Total cash from disposals 25 742 1 364

Cash provided by or used for investment activities (B) (134 022) (90 653) Financing activities

Capital increase 1 404

Net disposal (acquisition) of treasury shares

Dividends paid to shareholders of the Group (10 913) (7 216)

Dividends paid to minority interests of consolidated companies

Total cash from equity operations (10 913) (5 812)

Issue of long-term loans 87 914 10 912

Issue of short-term loans 229 79

Repayment of long-term loans (2 062) (3 436) Repayment of short-term loans (18 520) (20 576) Net interest expense paid (4 052) (2 593) Total cash from operations on loans and other financial liabilities 63 509 (15 614)

Cash provided by or used for financing activities (C) 52 596 (21 426)

Effect of change in foreign exchange rates (D) 122 4 686

Effect of adjustments in treasury shares (D) 1 018 1 434

Changes in net cash (A+B+C+D) (4 965) 1 954

Cash at January 1st (E) 72 957 71 003

Cash at year end (A+B+C+D+E) 67 992 72 957

Other short-term financial assets 51 883 58 619

Cash and cash equivalents 45 675 22 261

Short-term banking facilities (29 565) (7 923)

Closing cash position 67 993 72 957

Change in LISI Group consolidated shareholders' equity

(In €'000) Capital stock

Capital-linked premiums (Note 7.3)

Treasury shares

Consolidated reserves

Conversion reserves

Other income and expenses recorded directly as shareholders' equity

Profit for the period, group share

Group's share of shareholders' equity

Minority interests

Total shareholders

' equity

Shareholders' equity at January 1, 2010 21 508 69 853 (16 264) 378 745 (14 662) 2 159 9 422 450 764 -125 450 639

Profit (loss) for the period N (a) 32 924 32 924 -161 32 763

Translation differential (b) 12 270 12 270 54 12 324

Payments in shares (c) 789 232 1 021 1 021

Capital increase 65 950 1 015 389 1 404

Restatements of treasury shares (d) 1 236 627 1 864 1 864

Appropriation of N-1 earnings 9 422 (9 422)

Various (*) -1 086 (1 086) (1 086) Change in scope

Dividends distributed (7 216) (7 216) (7 216)

Reclassification (174) (527) (701) 701

Impact of deferred tax liabilities relative to CVAE (Tax on Companies' Added Value) (e)** (1 391) (1 391) (1 391)

Shareholders' equity at December 31, 2010 21 573 70 803 (15 202) 379 825 (2 392) 1 933 32 924 489 463 858 490 320

789 12 270 859 32 924 46 843

Profit (loss) for the period N (a) 58 225 58 225 (147) 58 078

Translation differential (b) 4 050 4 050 (42) 4 008

Payments in shares (c) 979 979 979

Capital increase

Restatements of treasury shares (d) (259) 113 (146) (146) Appropriation of N-1 earnings 32 924 (32 924) 0 0

Change in methods *** (1 428) (1 428) (1 428) Change in scope **** 789 789

Dividends distributed (10 913) (10 913) (10 913) Restatements of financial instruments (f) ***** 1 277 1 277 1 278

Various (e) (454) (454) (454)

Shareholders' equity at December 31, 2011 21 573 70 803 (15 461) 401 231 1 658 3 025 58 225 541 054 1 458 542 512

including total revenues and expenses posted for the period (a) +

(b) + ( c) + (d) + ( e) 4 050 1 092 58 225 63 367